The abstract is read at the publisher; the summary is JClub's.
MTD remote self-administered digital cognitive screening discriminated cognitively unimpaired from MCI/mild dementia with AUC=.89 (95% CI=.87–.92) in 2,131 CU and 118 impaired participants.
- Why it matters: Scalable cognitive characterization is needed to support Alzheimer’s disease treatment decisions, but remote, self-administered screening must be validated against clinical diagnoses and biomarker-defined groups.
- What they did: In a prospectively designed study, participants completed Mayo Test Drive remotely, while clinical diagnoses were set by multidisciplinary consensus independent of MTD; amyloid- and tau-PET were available for 1,224 for logistic-regression analyses.
- The result: MTD discrimination remained high for CU versus MCI (AUC=.88; 95% CI=.85–.92) and was highest for CU A- versus MCI/DEM A+ (AUC=.95; 95% CI=.92–.97), with biomarker-based comparisons comparable to Mayo-PACC and improved sensitivity using combined cutoffs and a two-stage framework.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.